Text Size

Expression Levels of RISC and Microprocessor Complex Components in Epithelial Skin Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01345760
First received: April 29, 2011
Last updated: October 15, 2012
Last verified: October 2012
History of Changes
  Purpose

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of the microprocessor complex subunit DGCR8 and the RISC components TARBP1, TARBP2, argonaute-1, argonaute-2 and PACT in epithelial skin cancer and its premalignant stage.


Condition
Skin Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Expression Levels of RNA-induced Silencing Complex (RISC) Components TARBP1, TARBP2, Argonaute-1, Argonaute-2, PACT and Microprocessor Complex Component DGCR8 in Epithelial Skin Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Skin Cancer
U.S. FDA Resources

Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention:   Samples With DNA

human skin


Enrollment: 44
Study Start Date: July 2008
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Basal Cell Carcinoma
Squamous Cell Carcinoma
Actinic Keratosis
healthy non-lesional skin

Detailed Description:

Patients with premalignant actinic keratoses, basal cell carcinomas and squamous cell carcinomas were included in the study. Punch biopsies were harvested from the center of the tumors, from sites of healthy skin and a healthy control group. DGCR8, TARBP1, TARBP2, argonaute-1, argonaute-2 and PACT mRNA expression levels were detected by quantitative real-time reverse transcriptase polymerase chain reaction.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with epithelial skin cancer and pre-malignant stages

Criteria

Inclusion Criteria:

  • epithelial skin cancer

Exclusion Criteria:

  • other known previous malignancies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01345760

Locations
Germany
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Study Director: Falk G Bechara, PD Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
  More Information

No publications provided

Responsible Party: Michael Sand, Dr., Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT01345760     History of Changes
Other Study ID Numbers: 1-Sand
Study First Received: April 29, 2011
Last Updated: October 15, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by Ruhr University of Bochum:
Basal Cell Carcinoma
Squamous Cell Carcinoma
Actinic Keratosis
microRNA
Dicer
Drosha
 RISC
microprocessor complex
Argonaute
DGCR8
TARBP

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases

ClinicalTrials.gov processed this record on June 17, 2013